APA (7th ed.) Citation

AP, K., S, K., Y, v. N., J, D., JA, D., CH, M., . . . MD, L. (2018). Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. Blood advances, 2(24), 3566. https://doi.org/10.1182/bloodadvances.2018019422

Chicago Style (17th ed.) Citation

AP, Kater, et al. "Obinutuzumab Pretreatment Abrogates Tumor Lysis Risk While Maintaining Undetectable MRD for Venetoclax + Obinutuzumab in CLL." Blood Advances 2, no. 24 (2018): 3566. https://doi.org/10.1182/bloodadvances.2018019422.

MLA (9th ed.) Citation

AP, Kater, et al. "Obinutuzumab Pretreatment Abrogates Tumor Lysis Risk While Maintaining Undetectable MRD for Venetoclax + Obinutuzumab in CLL." Blood Advances, vol. 2, no. 24, 2018, p. 3566, https://doi.org/10.1182/bloodadvances.2018019422.